iCAD (NASDAQ:ICAD) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of iCAD (NASDAQ:ICAD) in a report issued on Tuesday. The firm set a “sell” rating on the technology company’s stock.

A number of other equities research analysts have also weighed in on the stock. Laidlaw reissued a “hold” rating on shares of iCAD in a report on Thursday, April 17th. BTIG Research cut shares of iCAD from a “buy” rating to a “neutral” rating in a research note on Wednesday, April 16th. Finally, Craig Hallum downgraded iCAD from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 16th.

iCAD Stock Down 3.5%

NASDAQ ICAD opened at $3.82 on Tuesday. The company has a market cap of $104.84 million, a price-to-earnings ratio of -29.38 and a beta of 1.35. iCAD has a twelve month low of $1.18 and a twelve month high of $4.02. The business’s fifty day moving average is $2.79 and its 200 day moving average is $2.43.

iCAD (NASDAQ:ICAD) last posted its earnings results on Tuesday, May 13th. The technology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04. iCAD had a negative return on equity of 15.65% and a negative net margin of 17.81%. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.54 million.

Hedge Funds Weigh In On iCAD

Hedge funds and other institutional investors have recently made changes to their positions in the stock. waypoint wealth counsel raised its holdings in iCAD by 44.0% during the 4th quarter. waypoint wealth counsel now owns 14,400 shares of the technology company’s stock worth $26,000 after purchasing an additional 4,400 shares during the last quarter. Thompson Davis & CO. Inc. acquired a new stake in shares of iCAD during the fourth quarter worth $31,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in iCAD during the first quarter worth $40,000. Goldman Sachs Group Inc. bought a new position in iCAD during the first quarter worth $44,000. Finally, PKS Advisory Services LLC acquired a new position in iCAD in the fourth quarter valued at $53,000. 24.61% of the stock is owned by institutional investors and hedge funds.

About iCAD

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.